Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

Anthony R. Mato; Matthew S. Davids; Jeff Sharman; Lindsey E. Roeker; Neil Kay; Arnon P. Kater; Kerry Rogers; Meghan C. Thompson; Joanna Rhodes; Andre Goy; Alan Skarbnik; Stephen J. Schuster; Constantine S. Tam; Toby A. Eyre; Susan O'Brien; Chadi Nabhan; Nicole Lamanna; Clare Sun; Mazyar Shadman; John M. Pagel; Chaitra Ujjani; Danielle Brander; Catherine C. Coombs; Nitin Jain; Chan Y. Cheah; Jennifer R. Brown; John F. Seymour; Jennifer A. Woyach

doi:https://doi.org/10.1158/1078-0432.CCR-21-1237

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

Anthony R. Mato, Matthew S. Davids, Jeff Sharman, Lindsey E. Roeker, Neil Kay, Arnon P. Kater, Kerry Rogers, Meghan C. Thompson, Joanna Rhodes, Andre Goy, Alan Skarbnik, Stephen J. Schuster, Constantine S. Tam, Toby A. Eyre, Susan O'Brien, Chadi Nabhan, Nicole Lamanna, Clare Sun, Mazyar Shadman, John M. PagelChaitra Ujjani, Danielle Brander, Catherine C. Coombs, Nitin Jain, Chan Y. Cheah, Jennifer R. Brown, John F. Seymour, Jennifer A. Woyach

Research output: Contribution to journal › Article › Academic › peer-review

13 Citations (Scopus)

Abstract

The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes. Symptomatic patients previously treated with a BTK inhibitor (BTKi) and venetoclax represent a new and rapidly growing unmet need in CLL. Here, we define unmet needs in a modern treatment context. We also critically review the literature for PI3K inhibitors and chemoimmunotherapy and lack of data to support their utility following BTKis and venetoclax. Finally, we suggest opportunities to ensure the continued innovation for patients with CLL.

Original language	English
Pages (from-to)	603-608
Number of pages	6
Journal	Clinical Cancer Research
Volume	28
Issue number	4
Early online date	17 Nov 2021
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-1237
Publication status	Published - 15 Feb 2022

Access to Document

https://doi.org/10.1158/1078-0432.CCR-21-1237

Cite this

Mato, A. R., Davids, M. S., Sharman, J., Roeker, L. E., Kay, N., Kater, A. P., Rogers, K., Thompson, M. C., Rhodes, J., Goy, A., Skarbnik, A., Schuster, S. J., Tam, C. S., Eyre, T. A., O'Brien, S., Nabhan, C., Lamanna, N., Sun, C., Shadman, M., ... Woyach, J. A. (2022). Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare). Clinical Cancer Research, 28(4), 603-608. https://doi.org/10.1158/1078-0432.CCR-21-1237

@article{fd58feacf56747c686c0656da4cdc10f,

title = "Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)",

abstract = "The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes. Symptomatic patients previously treated with a BTK inhibitor (BTKi) and venetoclax represent a new and rapidly growing unmet need in CLL. Here, we define unmet needs in a modern treatment context. We also critically review the literature for PI3K inhibitors and chemoimmunotherapy and lack of data to support their utility following BTKis and venetoclax. Finally, we suggest opportunities to ensure the continued innovation for patients with CLL.",

author = "Mato, {Anthony R.} and Davids, {Matthew S.} and Jeff Sharman and Roeker, {Lindsey E.} and Neil Kay and Kater, {Arnon P.} and Kerry Rogers and Thompson, {Meghan C.} and Joanna Rhodes and Andre Goy and Alan Skarbnik and Schuster, {Stephen J.} and Tam, {Constantine S.} and Eyre, {Toby A.} and Susan O'Brien and Chadi Nabhan and Nicole Lamanna and Clare Sun and Mazyar Shadman and Pagel, {John M.} and Chaitra Ujjani and Danielle Brander and Coombs, {Catherine C.} and Nitin Jain and Cheah, {Chan Y.} and Brown, {Jennifer R.} and Seymour, {John F.} and Woyach, {Jennifer A.}",

note = "Funding Information: A.P. Kater reports grants and other support from Janssen, AbbVie, BMS, Roche, and AstraZeneca and other support from Lava outside the submitted work. J. Rhodes reports personal fees from Pharmacyclics, AstraZeneca, Beigene, SeaGen, TG Therapeutics, AbbVie, Genentech, and Verastem and other support from LOXO outside the submitted work. S.J. Schuster reports grants and personal fees from Acerta, AbbVie, Celgene, Genentech/Roche, Novartis, Incyte, and Juno Therapeutics; personal fees from AstraZeneca, BeiGene, Janssen, Morphosys, Regeneron, Legend Biotech, Mustang Biotech, Nordic Nanovector, and AlloGene; and grants from Merck and TG Therapeutics outside the submitted work. C.S. Tam reports other support from Beigene, Janssen, and AbbVie during the conduct of the study. S. O{\textquoteright}Brien reports other support from AbbVie, Acerta, Alexion, Amgen, Aptose Biosciences Inc., Astellas, Autolus, Bristol Myers Squibb, Caribou, Celgene, DynaMed, Eli Lilly and Company, Gilead, GlaxoSmithKline, Janssen Oncology, Johnson and Johnson, Juno Therapeutics, Kite, MEI Pharma Inc., Merck, NOVA Research Company, Pfizer, PCYC, Regeneron, Sunesis, TG Therapeutics, Vaniam Group LLC, Verastem, and Vida Ventures during the conduct of the study. N. Lamanna reports grants and personal fees from AbbVie, AstraZeneca, BeiGene, Genentech, Juno, and Eli Lilly/Loxo; personal fees from Janssen and Pharmacyclics; and grants from Oncternal, Octapharma, MingSight, TG Therapeutics outside the submitted work. C. Sun reports grants from Genmab outside the submitted work. M. Shadman reports personal fees from AbbVie, Genentech, AstraZeneca, Sound Biologics, Pharmacyclics, Beigene, Bristol Myers Squibb, Morphosys, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, Eli Lilly, Adaptimmune, Mustang Bio, Regeneron, and Atara Biotherapeutics and grants from Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, AbbVie, TG Therapeutics, Beigene, AstraZeneca, Sunesis, Atara Biotherapeutics, and GenMab outside the submitted work. J.M. Pagel reports other support from Gilead, AstraZeneca, Beigene, and Incyte outside the submitted work. C. Ujjani reports personal fees from Atara, Epizyme, AbbVie, Pharmacyclics, Janssen, TG Therapeutics, Beigene, Incyte, Eli Lilly, Adaptive Therapeutics, Adaptive Biotechnologies, AstraZeneca, Morphosys, Gilead, and Verastem outside the submitted work. N. Jain reports grants, personal fees, and non-financial support from Pharmacyclics, AbbVie, Genentech, AstraZeneca, Servier, ADC Therapeutics, Cellectis, Precision Biosciences, and Janssen; grants and non-financial support from BMS, Pfizer, Incyte, Fate Therapeutics, Mingsight, Takeda, Medisix, and Loxo Oncology; grants and personal fees from Adaptive Biotechnologies; grants from Aprea Therapeutics and Novalgen; and personal fees from Beigene, TG Therapeutics, MEI Pharma, and CareDx outside the submitted work. C.Y. Cheah reports grants and personal fees from Roche, BMS, and MSD; grants from AbbVie; and personal fees from Loxo at Lilly, TG Therapeutics, AstraZeneca, Novartis, Gilead, and Janssen during the conduct of the study. No disclosures were reported by the other authors. Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research",

year = "2022",

month = feb,

day = "15",

doi = "https://doi.org/10.1158/1078-0432.CCR-21-1237",

language = "English",

volume = "28",

pages = "603--608",

journal = "Clinical Cancer Research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "4",

}

Mato, AR, Davids, MS, Sharman, J, Roeker, LE, Kay, N, Kater, AP, Rogers, K, Thompson, MC, Rhodes, J, Goy, A, Skarbnik, A, Schuster, SJ, Tam, CS, Eyre, TA, O'Brien, S, Nabhan, C, Lamanna, N, Sun, C, Shadman, M, Pagel, JM, Ujjani, C, Brander, D, Coombs, CC, Jain, N, Cheah, CY, Brown, JR, Seymour, JF & Woyach, JA 2022, 'Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)', Clinical Cancer Research, vol. 28, no. 4, pp. 603-608. https://doi.org/10.1158/1078-0432.CCR-21-1237

TY - JOUR

T1 - Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL

T2 - “What's Past Is Prologue” (Shakespeare)

AU - Mato, Anthony R.

AU - Davids, Matthew S.

AU - Sharman, Jeff

AU - Roeker, Lindsey E.

AU - Kay, Neil

AU - Kater, Arnon P.

AU - Rogers, Kerry

AU - Thompson, Meghan C.

AU - Rhodes, Joanna

AU - Goy, Andre

AU - Skarbnik, Alan

AU - Schuster, Stephen J.

AU - Tam, Constantine S.

AU - Eyre, Toby A.

AU - O'Brien, Susan

AU - Nabhan, Chadi

AU - Lamanna, Nicole

AU - Sun, Clare

AU - Shadman, Mazyar

AU - Pagel, John M.

AU - Ujjani, Chaitra

AU - Brander, Danielle

AU - Coombs, Catherine C.

AU - Jain, Nitin

AU - Cheah, Chan Y.

AU - Brown, Jennifer R.

AU - Seymour, John F.

AU - Woyach, Jennifer A.

N1 - Funding Information: A.P. Kater reports grants and other support from Janssen, AbbVie, BMS, Roche, and AstraZeneca and other support from Lava outside the submitted work. J. Rhodes reports personal fees from Pharmacyclics, AstraZeneca, Beigene, SeaGen, TG Therapeutics, AbbVie, Genentech, and Verastem and other support from LOXO outside the submitted work. S.J. Schuster reports grants and personal fees from Acerta, AbbVie, Celgene, Genentech/Roche, Novartis, Incyte, and Juno Therapeutics; personal fees from AstraZeneca, BeiGene, Janssen, Morphosys, Regeneron, Legend Biotech, Mustang Biotech, Nordic Nanovector, and AlloGene; and grants from Merck and TG Therapeutics outside the submitted work. C.S. Tam reports other support from Beigene, Janssen, and AbbVie during the conduct of the study. S. O’Brien reports other support from AbbVie, Acerta, Alexion, Amgen, Aptose Biosciences Inc., Astellas, Autolus, Bristol Myers Squibb, Caribou, Celgene, DynaMed, Eli Lilly and Company, Gilead, GlaxoSmithKline, Janssen Oncology, Johnson and Johnson, Juno Therapeutics, Kite, MEI Pharma Inc., Merck, NOVA Research Company, Pfizer, PCYC, Regeneron, Sunesis, TG Therapeutics, Vaniam Group LLC, Verastem, and Vida Ventures during the conduct of the study. N. Lamanna reports grants and personal fees from AbbVie, AstraZeneca, BeiGene, Genentech, Juno, and Eli Lilly/Loxo; personal fees from Janssen and Pharmacyclics; and grants from Oncternal, Octapharma, MingSight, TG Therapeutics outside the submitted work. C. Sun reports grants from Genmab outside the submitted work. M. Shadman reports personal fees from AbbVie, Genentech, AstraZeneca, Sound Biologics, Pharmacyclics, Beigene, Bristol Myers Squibb, Morphosys, TG Therapeutics, Innate Pharma, Kite Pharma, Adaptive Biotechnologies, Epizyme, Eli Lilly, Adaptimmune, Mustang Bio, Regeneron, and Atara Biotherapeutics and grants from Mustang Bio, Celgene, Bristol Myers Squibb, Pharmacyclics, Gilead, Genentech, AbbVie, TG Therapeutics, Beigene, AstraZeneca, Sunesis, Atara Biotherapeutics, and GenMab outside the submitted work. J.M. Pagel reports other support from Gilead, AstraZeneca, Beigene, and Incyte outside the submitted work. C. Ujjani reports personal fees from Atara, Epizyme, AbbVie, Pharmacyclics, Janssen, TG Therapeutics, Beigene, Incyte, Eli Lilly, Adaptive Therapeutics, Adaptive Biotechnologies, AstraZeneca, Morphosys, Gilead, and Verastem outside the submitted work. N. Jain reports grants, personal fees, and non-financial support from Pharmacyclics, AbbVie, Genentech, AstraZeneca, Servier, ADC Therapeutics, Cellectis, Precision Biosciences, and Janssen; grants and non-financial support from BMS, Pfizer, Incyte, Fate Therapeutics, Mingsight, Takeda, Medisix, and Loxo Oncology; grants and personal fees from Adaptive Biotechnologies; grants from Aprea Therapeutics and Novalgen; and personal fees from Beigene, TG Therapeutics, MEI Pharma, and CareDx outside the submitted work. C.Y. Cheah reports grants and personal fees from Roche, BMS, and MSD; grants from AbbVie; and personal fees from Loxo at Lilly, TG Therapeutics, AstraZeneca, Novartis, Gilead, and Janssen during the conduct of the study. No disclosures were reported by the other authors. Publisher Copyright: © 2021 American Association for Cancer Research

PY - 2022/2/15

Y1 - 2022/2/15

N2 - The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes. Symptomatic patients previously treated with a BTK inhibitor (BTKi) and venetoclax represent a new and rapidly growing unmet need in CLL. Here, we define unmet needs in a modern treatment context. We also critically review the literature for PI3K inhibitors and chemoimmunotherapy and lack of data to support their utility following BTKis and venetoclax. Finally, we suggest opportunities to ensure the continued innovation for patients with CLL.

AB - The management of chronic lymphocytic leukemia (CLL) has undergone unprecedented changes over the last decade. Modern targeted therapies are incorporated into clinical practice. Unfortunately, patients have begun to develop resistance or intolerance to multiple classes. Symptomatic patients previously treated with a BTK inhibitor (BTKi) and venetoclax represent a new and rapidly growing unmet need in CLL. Here, we define unmet needs in a modern treatment context. We also critically review the literature for PI3K inhibitors and chemoimmunotherapy and lack of data to support their utility following BTKis and venetoclax. Finally, we suggest opportunities to ensure the continued innovation for patients with CLL.

UR - http://www.scopus.com/inward/record.url?scp=85124992369&partnerID=8YFLogxK

U2 - https://doi.org/10.1158/1078-0432.CCR-21-1237

DO - https://doi.org/10.1158/1078-0432.CCR-21-1237

M3 - Article

C2 - 34789482

SN - 1078-0432

VL - 28

SP - 603

EP - 608

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 4

ER -

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

Abstract

Access to Document

Other files and links

Cite this